 Omeros Biologics License Application BLA for orphan drug narsoplimab was accepted by FDA and was given priority review with FDA action date of July 17, 2021. This BLA is for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy HSCT-TMA, a rare, unmet, life-threatening disease. 